Suvorexant to be investigated for improving sleep and PTSD symptoms post-exposure therapy
Background
Posttraumatic Stress Disorder (PTSD) is a severe consequence of trauma, often leading to hyperarousal and significant sleep disturbances. Poor sleep is a common complaint among Veterans with PTSD, impairing concentration, memory, and contributing to physical health issues. The orexin system plays a key role in wakefulness and arousal. Blocking this system with compounds like suvorexant may mitigate PTSD-related sleep problems and improve therapeutic outcomes. This study addresses the gap in understanding how targeting sleep post-therapy impacts PTSD recovery.
Study Design
This is a Phase 4 clinical trial (NCT03642028) with an estimated enrollment of 190 participants. The study aims to examine the effects of blocking the orexin system with suvorexant after exposure-based intervention for PTSD. Primary endpoints include sleep quality, PTSD symptoms, and intersession habituation. Secondary measures will include objectively measured wrist actigraphy and PTSD-related nightmares using the Pittsburgh Sleep Quality Index-PTSD addendum (PSQI-A). The study is currently recruiting, with an estimated completion date of 2025-12-31.
Why It Matters
If successful, this study could establish suvorexant as a valuable adjunctive therapy for Veterans with PTSD undergoing exposure-based interventions. Improving sleep quality post-therapy may enhance the benefits of trauma processing, potentially leading to more robust and lasting symptom reduction. This could translate into a new clinical protocol where suvorexant is prescribed to optimize therapeutic exposure and prevent sleep-related setbacks. Understanding the impact on intersession habituation and nightmares could refine treatment strategies, offering a more comprehensive approach to managing PTSD and improving patient quality of life.
suvorexant
ptsd
sleep-disturbance
orexin-antagonist
clinical-trial
veterans